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Abstract
Background: Inorganic nanoparticles provide promising tools for biomedical applications including detection, diagnosis
and therapy. While surface properties such as charge are expected to play an important role in their in vivo behavior, very
little is known how the surface chemistry of nanoparticles influences their pharmacokinetics, tumor uptake, and
biodistribution.
Method/Principal Findings: Using a family of structurally homologous nanoparticles we have investigated how
pharmacological properties including tumor uptake and biodistribution are influenced by surface charge using neutral
(TEGOH), zwitterionic (Tzwit), negative (TCOOH) and positive (TTMA) nanoparticles. Nanoparticles were injected into mice
(normal and athymic) either in the tail vein or into the peritoneum.
Conclusion: Neutral and zwitterionic nanoparticles demonstrated longer circulation time via both IP and IV administration,
whereas negatively and positively charged nanoparticles possessed relatively short half-lives. These pharmacological
characteristics were reflected on the tumor uptake and biodistribution of the respective nanoparticles, with enhanced
tumor uptake by neutral and zwitterionic nanoparticles via passive targeting.
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Introduction
The limited solubility, stability, and short circulation time of
traditional therapeutic agents can introduce side effects and
unwanted accumulation of therapeutics into non-diseased tissue
[1]. Multimodal nanoparticles, polymer-drug conjugates, mono-
clonal antibodies and immunoconjugates provide a means of
increasing therapeutic efficacy [2], while also providing new
therapeutic and imaging modalities [3]. The diversity of available
structures and core materials [4,5] coupled with sub-cellular size
and biocompatibility have generated numerous applications of
these materials in fields ranging from delivery [6–8] and imaging
[9], to photothermal ablation of tumors [10,11].
Key issues for the creation of effective nanotherapeutics include
(i) overcoming biological barriers, (ii) specific accumulation of the
therapeutic at the target site (i.e, targeting), and (iii) preventing
rapid clearance [12]. While there have been a number of studies
on the effects of particle size on biodistribution [13], little is known
about the effect of surface charge on biodistribution and
pharmacokinetics of nanoparticles, as these studies have generally
used neutral poly(ethylene glycol) (PEG) functionalization [14].
This ‘‘stealth’’ coverage decreases the rate of opsonization,
providing more efficient transport to the target tissue, e.g. tumor.
The neutral coating provided by PEG coverage provides one route
to enhanced bioavailability. Charged systems including zwitter-
ionic surfaces [15], however, provide an alternative means of
dictating the bioavailability of nanomaterials. To date, there has
not been a detailed statistically robust investigation on how the
surface charge of nanosystems impact their biodistribution,
pharmacokinetics and tumor uptake.
In the current study, we systematically investigate the role of
the surface charge of engineered gold nanoparticles in dictating
the pharmacokinetics, and hence the biodistribution and tumor
uptake of these nanomaterials. As the biodistribution of drug
carriers is dependent upon the route of administration [16], we
administered these particles using both intravenous (IV) and
intraperitoneal (IP) routes [17]. We first assessed how surface
charge impacts pharmacokinetics (PK) and biodistribution of the
particles in a mouse model, demonstrating that surface charge
determines circulation time of gold nanoparticles in the blood and
tumor uptake through passive targeting. Through these studies,
we reveal that surface charge and mode of administration has
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24374tremendous consequences on nanoparticle behavior in vivo, thus
providing insight for the improved design in nanoparticle
therapeutics.
Results
Nanoparticle Fabrication
Our studies used gold nanoparticles (AuNP) featuring 2 nm
diameter cores, with overall hydrodynamic diameters of ,9–
10 nm. As shown in Figure 1, all nanoparticles contain a
hydrophobic interior that confers stability [18] and a tetra(ethylene
glycol) functionality to provide compatibility and solubility in cell
culture media and other biological fluids. The interactions of these
particles are dictated by the choice of headgroups, facilitating the
determination of structure-activity correlations [19]. These particles
are also exceptionally stable in biofluids [20], rendering them useful
as drug delivery vehicles [21] and in sensing [22]. To provide a
concise study of the role of charge in bioavailability, AuNPs
featuring anionic, cationic and zwitterionic particle surfaces were
fabricated using ligands having the appropriate headgroups [23].
These particles have been shown to be stable against aggregation in
serum and have relatively low toxicities in both in vitro cell assays
[24] and in fish [25]. Central to our studies, the common structure
shared by these particles allows direct assessment of the role of
charge on in vivo behavior (see Figure S1).
Plasma Pharmacokinetics is affected by nanoparticle
surface charge
The plasma dispositions of the AuNPs were characterized in
male CD1 mice after IV and IP administration. Plasma con-
centration-time profiles for each AuNP are illustrated in Figure 2,
with the pharmacokinetic parameters are summarized in Table 1.
High peak plasma concentrations (Cmax) .80 mg/ml were
achieved with IV injection of the negative (TCOOH), neutral
(TEGOH) and zwitterionic (TZwit) particles, while a 10-fold
lower peak plasma concentration was achieved with the positive
(TTMA) particles (Table 1). Following IV injection, high plasma
clearance was observed for the negative (TCOOH) and positive
(TTMA) charged AuNPs (0.0739 mg/ml/min and 0.170 mg/ml/
min, respectively) such that the plasma concentrations fell below
1 mg/ml within 15 minutes after injection (Figure 1A). In
contrast, plasma clearance for the neutral (TEGOH) and
zwitterionic (TZwit) particles was substantially lower
(0.00605 mg/ml/min and 0.00561 mg/ml/min, respectively) such
that plasma concentrations remained above 1 mg/ml 24 hours
Figure 1. Structural representation of gold nanoparticles (2 nm
core diameter) used. Gold nanoparticles (AuNPs) of different surface
charges were generated by chemical modification of the terminal
portion of the ligand bonded to the nanoparticle core. Four types of
AuNPs were used neutral (TEGOH), positive (TTMA), negative (TCOOH)
and zwitterionic (TZwit). The surface charge was measured by zeta
potential.
doi:10.1371/journal.pone.0024374.g001
Figure 2. Plasma profiles for gold nanoparticles. Normal mice
were injected either (A) intravenously or (B) intraperitoneally. Data
points are the mean +/2 SEM from n=3 animals.
doi:10.1371/journal.pone.0024374.g002
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(,1 mg/ml) of the negative (TCOOH) and positive (TTMA)
AuNPs were detected in the circulation (Figure 2B). In marked
contrast, the neutral (TEGOH) and zwitterionic (TZwit) AuNPs
rapidly entered into circulation, with peak concentrations above
10 mg/ml achieved 1.5 and 3 hours, respectively. As with the IV
injection, plasma concentrations of the neutral (TEGOH) and
zwitterionic (TZwit) AuNPs remained above 1 mg/ml 24 hours
after injection (Figure 2B) and bioavailability values for these
AuNP were high (77% and 70%, respectively). From these results,
it is apparent that nanoconjugates with neutral and zwitterionic
properties maximize the circulation time.
Tumor Uptake of AuNPs is related to circulation resident
time
Passive targeting of nanomaterials via the enhanced permeabil-
ity and retention (EPR) effect is dependent on their blood resident
time [26]. Our hypothesis was that the neutral and zwitterionic
nanoconjugates would exhibit increased tumor uptake relative
to negative and positively charged analogs. As expected, the
nanoparticles with a long retention time in circulation (TEGOH
and TZwit) accumulated more efficiently into the tumor
(Figure 3). After 24 hours post-injection (200 mg per mouse via
tail vein or intraperitoneal), subcutaneously implanted ovarian
tumor-bearing athymic nude mice were euthanized and the
tumors were analyzed for gold content. The TZwit and TEGOH
nanoparticles had substantially higher tumor uptake irrespective of
the mode of administration. When injected into the peritoneum, a
minute amount of the charged particles accumulated in the tumor,
as expected from our pharmacokinetic studies. However, the
negative nanoparticle TCOOH accumulated in the tumor after
IV injection whereas the positive particle TTMA did not. These
results are consistent with the pharmacokinetics of the IV
administered nanoparticles. Thus, as a result of improved phar-
macokinetics, neutral and zwitterionic particles demonstrated
increased tumor accumulation with both routes of administration
ascompared tothe othernanoparticles throughtheEPR(Enhanced
Permeability and Retention) effect [27]. Our studies are in
agreement with previous reports indicating that long plasma half-
life can lead to increased tumor uptake [28], an important goal in
imaging, diagnostics and therapeutics [29].
Ligand end group influences biodistribution of AuNPs
To determine the role of particle charge in regulating the
biodistribution of these engineered nanomaterials, we compared
the organ distribution of the AuNPs in immunocompetent mice
(IV vs. IP, Table 2). After IV injection the nanoparticles were
predominantly localized in the liver and spleen (Figure 4B), with
little particle found in the brain, kidneys, or lungs. In contrast,
24 hours after IP injection the concentration of gold was the
highest in the pancreas (Figure 4A) for all four particles. This
localization may arise from intraperitoneal circulation and altered
lymphatic clearance [30]; nanoparticles are removed from
systemic circulation through the permeable vascular endothelium
in lymph nodes [27,31]. The difference in localization demon-
strates that the mode of administration of AuNPs affects the level
of particle uptake in different tissues. Moreover, the levels of
AuNPs found in the liver and spleen indicate that RES is the
dominant mode of clearance for these particles.
Discussion
In recent years, inorganic nanoparticles have emerged as drug
delivery systems [32], imaging agents [29] and diagnostic
biosensors [33]. However, the biological fate and effect of
nanoparticles in living systems needs to be defined in order to
improve therapeutic engineering for in vivo applications, including
Table 1. AuNP Pharmacokinetics Summary.
IV IP
TEGOH TTMA TCOOH TZwit TEGOH TTMA TCOOH TZwit
Cmax (mg/ml) 82.93 7.88 97.48 115.13 18.61 0.50 1.32 23.45
Tmax ( m i n ) 55559 0 2 1 0 9 0 2 1 0
t1/2 (min) 304 1428 18 229 784 1079 1178 287
AUC0-‘ (mg/ml*min) 2.65E04 1.02E03 3.03E03 2.98E04 2.65E04 1.02E03 3.03E03 2.98E04
CLp (ml/min) 6.05E-03 1.70E-01 7.38E-02 5.60E-03
F( % )
{ 78 86 14 70
Dose (mg): TEGOH 160, TTMA 174, TCOOH 224, TZwit 167.
{F=AUCi.p./AUCi.v.6100; Cmax=Peak plasma concentration; CLp (ml/min)=Plasma clearance; Tmax=Time.
doi:10.1371/journal.pone.0024374.t001
Figure 3. Quantification of in vivo accumulation of gold
nanoparticles into tumors. Coinciding with the blood concentration,
nanoparticles that showed a long retention time in circulation were
able to extravasate and accumulate into the tumor. Data points are the
mean +/2 SEM from n=5 animals.
doi:10.1371/journal.pone.0024374.g003
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this field has primarily focused on the biodistribution of inorganic
nanoparticles based on their size. In our studies we maintained a
constant particle size while varying the surface properties of the
nanoparticle (see Figure S1, S2, and S3). Using pegylated gold
nanoparticles, we investigated the pharmacokinetics, tumor
uptake, and biodistribution of 2 nm diameter core/10 nm overall
(Figure 1) particles, focusing on the effect of surface charge on in
vivo behavior. Blood sampling revealed that the neutral and
zwitterionic particles TEGOH and TZwit AuNPs provided the
highest concentrations and IP bioavailability. These concentra-
tions were sustained over the 24-hour study period. The particle
pharmacokinetics after IP injection was likewise strongly depen-
dent upon particle surface charge. Plasma clearance was very low
in comparison to the charged AuNPs (Figure 2). This marked
difference in bioavailability could be primarily due to opsonization
of the nanoparticles with antibodies for recognition by resident
macrophages. With the high concentration of phagocytes in the
RES, opsonized particles are cleared out within minutes. Previous
reports have also indicated that positively charged polymeric and
hybrid nanoparticles accumulate in the liver and spleen in spite of
PEG functionalization [36,37]. However, we show by modifying
the nanoparticle surface charge, the pharmacokinetics of the
engineered nanoparticles can be tuned.
One of the major issues facing pharmacological agents is tissue
selectivity [38]. Since the window of delivery of therapeutic agents
is often limited it is imperative that penetration into highly
vascular tumors is efficient. Accumulation in the tumor environ-
ment determines the therapeutic efficacy of antitumor therapeu-
tics. However, this accumulation is diminished by non-specific
tissue uptake and clearance by the RES. By utilizing the EPR
effect, it is possible for long-circulating nanoparticles to reach and
accumulate in the tumor [27]. In our studies, the more
bioavailable TEGOH and TZwit nanoparticles exhibited a
significantly tumor uptake over the TTMA particles after IV
injection. Futhermore, with IV injections, TCOOH along with
the TTMA and TEGOH nanoparticles had increased tumor
uptake compared to the TTMA nanoparticle. Previous reports
have also observed that a long plasma half-life can lead to
increased tumor uptake [14], enabling biomedical applications
such as imaging, diagnostic and therapeutics.
While all of the nanoparticles used in this study had a
pronounced uptake in the liver following IP injection, it is
interesting to note that when injected through the tail vein,
TCOOH and TZwit uptake in the liver was considerable
compared to the other nanoparticles. Previous reports have shown
that b-2 glycoprotein and apolipoprotein B are known to bind to
negatively-charged surfaces [39]. These proteins attach to foreign
substances forming lipoproteins and transport them though the
body via the lymphatic system or blood. Since both proteins are
hepatic, it is possible that the TCOOH and TZwit nanoparticles
are being sequestered to the liver due to the negative entity of their
headgroup. Another interesting point is that IP injection resulted
in high levels of particles in the pancreas. This localization
may arise from intraperitoneal circulation and altered lymphatic
Table 2. Biodistribution Study.
Brain (mg/g) Lung (mg/g) Liver (mg/g) Pancreas (mg/g) Spleen (mg/g) Kidney (mg/g)
IP IV IP IV IP IV IP IV IP IV IP IV
TEGOH 4.8 0.441 39.9 6.471 117.2 84.5 151.6 2.063 46.1 36.8 20.16 4.5
TTMA 4.7 0.268 26.4 2.339 96.6 30.8 218.2 0.660 110.2 22.7 21.04 2.8
TCOOH 4.8 0.174 25.5 32.737 130.7 154.8 288.4 2.632 86.9 43.1 21.08 3.6
TZwit 5.2 1.070 35.6 20.926 97.3 156.0 212.2 9.334 82.9 30.4 37.88 13.7
Dose (mg): TEGOH 160, TTMA 174, TCOOH 224, TZwit 167.
doi:10.1371/journal.pone.0024374.t002
Figure 4. Tissue distribution of gold nanoparticles in mice. In
vivo mean gold concentration (mg) per gram of organ 24 hours post (A)
IP injection and (B) IV injection. The mode of administration and the
ligand end group of AuNPs affects the level of gold uptake in different
tissues with the RES being the dominant mode of clearance. Data points
are the mean +/2 SEM from n=5 animals. Results are reported as gold
concentration (mg) per gram of organ.
doi:10.1371/journal.pone.0024374.g004
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tion through the permeable vascular endothelium in lymph nodes
[27,31].
In conclusion, charge is a key determinant of the interactions of
biological and synthetic materials with biosystems. We have
quantified the role of surface charge on pharmacokinetics, tumor
uptake and biodistribution using a structurally consistent family of
neutral, zwitterionic, negative and positive gold nanoparticles
(2 nm core, 10 nm overall diameter, see Figures S1 and S2).
Neutral and zwitterionic particles provide high systemic exposure
and low clearance when administered through intravenous
administration and are rapidly absorbed in the circulation after
intraperitoneal administration. Negative particles provide moder-
ate systemic exposure while positive particles are rapidly cleared.
Both positive and negative particles are poorly absorbed in the
circulation after intraperitoneal administration, indicating the
inability of these particles to cross the peritoneal barrier. Low
plasma clearance for both administration routes is reflected in the
increased tumor uptake of the neutral and zwitterionic nanopar-
ticles in a subcutaneously implanted xenograft model of ovarian
cancer. Biodistribution studies in different mouse strains (immu-
nodeficient vs. immunocompetent) demonstrate that surface
charge of the nanoparticles and their modes of systemic admini-
stration uniquely alter their pharmacokinetics, organ distribution
and tumor uptake. The ability of surface charge to dictate
bioavailability provides critical information to improve the design
of nanotherapeutics for enhanced tumor uptake by both passive
and active targeting strategies.
Materials and Methods
Gold nanoparticle synthesis and characterization
The Brust-Schiffrin two-phase synthesis method [40,41] was
used for synthesis of AuNPs with core diameters around 2 nm
(Figure S1). After that, Murray place-exchange method was used
to obtain functionalized AuNPs (Figure S3) [22,42].
Animals
All experiments were done under protocols approved by the
Mayo Clinic Institutional Animal Care and Use Committee
(Protocol No A14108). Male HEJ/C3H mice, 4–6 weeks old and
athymic mice (4–6 week old) were obtained from NCI Repository
(Fredrick, MD). Male CD1 mice (,20 g) were received from
Charles River.
Pharmacokinetics
AuNPs (100 mLo f4 0mM) were administered to male CD1
mice (20 g) intravenously (IV) via the lateral tail vein and
intraperitoneally (IP) in the right side of the stomach using a
tuberculin syringe fitted with a 27-gauge needle. Blood samples
were collected 5, 15, 30, 60, 90, 210, 480 and 1440 min post-
injection. Mice were anesthetized under isoflurane vapors and
blood samples collected by cardiac puncture using a 10% heparin
in citrate phosphate dextrose solution anticoagulant (150 mL
anticoagulant/ml whole blood), transferred to silanized amber
microcentrifuge tubes and immediately chilled on ice. After
separation by centrifugation (10,000 rpm 63 min at 4uC) plasma
was transferred to silanized amber microcentrifuge tubes and
immediately frozen. Samples were stored at 270uC until analysis.
AuNP plasma concentration–time data were analyzed by standard
noncompartmental methods using the program WinNonlin Pro
(Pharsight Corp, Mountain View, CA).
Cell Culture
CP-70 cells were grown and maintained in RPMI medium
supplemented with 10% fetal bovine serum and 1% antibiotic-
antimycotic. Cultures were maintained at 37uC and 5% CO2
atmosphere.
Tumor Xenograft
The animal use protocol was approved by the Mayo Clinic
Animal Care and Use Committee (IACUC). CP-70 cells were
lifted from tissue culture dishes using trypsin (16) and pelleted at
1500 rpm. Cells were resuspended in HBSS and counted using a
hemocytometer. A 100 mL volume containing 2610
6 cells was
injected subcutaneously on the right flank of 4–6 week old male
athymic mice. Tumor growth was monitored until the mass
reached 0.5 cm in length in any direction.
Biodistribution Study
The mice were randomized prior to nanoparticle injection. Mice
were injected with 200 mg of AuNPs via IP or IV injections. After
24 hours, the mice were euthanized by CO2 asphyxiationand tissue
was collected for analysis. Total uptake of gold was analyzed using
Instrumental Neutron Activation Analysis (INAA) [43].
Supporting Information
Figure S1 TEM images of the gold nanoparticles used in
the study.
(TIF)
Figure S2 DLS measurements of nanoparticle size
(1 uM of AuNPs in PB 5 mM, pH 7.4).
(TIF)
Figure S3 Charge distribution of the functionalized gold
nanoparticles used in the study (1 uM of AuNPs in 5 mM
PBS, pH 7.4).
(TIF)
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